Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Open Access
- 22 August 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 122 (8), 1376-1383
- https://doi.org/10.1182/blood-2013-02-483073
Abstract
Key Points Bortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients ≥70 years, suggesting the need of a more careful patient selection.Keywords
This publication has 28 references indexed in Scilit:
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 TrialJournal of Clinical Oncology, 2012
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyThe Lancet, 2010
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyBlood, 2010
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialThe Lancet, 2007
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996